Novavax’s Phase III RSV Vaccine Failure Wipes Out Nearly $2bn In Value

Novavax shocked investors with negative results for its RSV vaccine in a Phase III clinical trial immunizing older adults, but promised more data – and ideas for a potential second Phase III trial – in October.